ArticleThe Journal of clinical investigation2014
Abnormal B cell memory subsets dominate HIV-specific responses in infected individuals.
Article in The Journal of clinical investigation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 129 citations in OpenAlex.
- The Antigen Presenting Potential of CD21Frontiers in immunology · 2020Trial
- PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection.The Journal of clinical investigation · 2018Trial
- Monitoring of dynamic changes in Keyhole Limpet Hemocyanin (KLH)-specific B cells in KLH-vaccinated cancer patients.Scientific reports · 2017Trial
- Longitudinal dynamics of the HIV-specific B cell response during intermittent treatment of primary HIV infection.PloS one · 2017Trial
- Beneficial Effects of cART Initiated during Primary and Chronic HIV-1 Infection on Immunoglobulin-Expression of Memory B-Cell Subsets.PloS one · 2015Trial
- Interferon-Mediated Regulation of Memory B Cell Identity and Function.Immunological reviews · 2026Review
- Central nervous system B cell multiomics reveals a legacy of immune dysregulation in long-term treated HIV infection.Science advances · 2026Article
- Human CD21Journal of human immunity · 2026Review
- High affinity is insufficient for strong B cell activation by HIV broadly neutralising antibodies.NPJ vaccines · 2026Article
- Multifaceted B cell response to transient HIV viremia in elite controllers.PLoS pathogens · 2026Article
- Incomplete B-cell reconstitution in ART-treated people living with HIV is associated with EBV-linked lymphoma progression.Frontiers in immunology · 2026Article
- The Impact of HIV on B Cell Compartment and Its Implications for COVID-19 Vaccinations in People with HIV.Vaccines · 2024Review
- Impact of HIV-Related Immune Impairment of Yellow Fever Vaccine Immunogenicity in People Living with HIV-ANRS 12403.Vaccines · 2024Article
- Type I interferons induce an epigenetically distinct memory B cell subset in chronic viral infection.Immunity · 2024Article
- Children with perinatally acquired HIV exhibit distinct immune responses to 4CMenB vaccine.JCI insight · 2024Article
- Detection of Lymphocytic Choriomeningitis Virus-Specific Memory B Cells Using Antigen Tetramers.Methods in molecular biology (Clifton, N.J.) · 2024Article
- HIV-1 treatment timing shapes the human intestinal memory B-cell repertoire to commensal bacteria.Nature communications · 2023Article
- Review
- A cluster of broadly neutralizing IgG against BK polyomavirus in a repertoire dominated by IgM.Life science alliance · 2023Article
- A close-up on the expanding landscape of CD21-/low B cells in humans.Clinical and experimental immunology · 2022Review
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Funding
Abstract
Recently, several neutralizing anti-HIV antibodies have been isolated from memory B cells of HIV-infected individuals. Despite extensive evidence of B cell dysfunction in HIV disease, little is known about the cells from which these rare HIV-specific antibodies originate. Accordingly, we used HIV envelope gp140 and CD4 or coreceptor (CoR) binding site (bs) mutant probes to evaluate HIV-specific responses in peripheral blood B cells of HIV-infected individuals at various stages of infection. In contrast to non-HIV responses, HIV-specific responses against gp140 were enriched within abnormal B cells, namely activated and exhausted memory subsets, which are largely absent in the blood of uninfected individuals. Responses against the CoRbs, which is a poorly neutralizing epitope, arose early, whereas those against the well-characterized neutralizing epitope CD4bs were delayed and infrequent. Enrichment of the HIV-specific response within resting memory B cells, the predominant subset in uninfected individuals, did occur in certain infected individuals who maintained low levels of plasma viremia and immune activation with or without antiretroviral therapy. The distribution of HIV-specific responses among memory B cell subsets was corroborated by transcriptional analyses. Taken together, our findings provide valuable insight into virus-specific B cell responses in HIV infection and demonstrate that memory B cell abnormalities may contribute to the ineffectiveness of the antibody response in infected individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.